[go: up one dir, main page]

HK1098155A1 - Nicotinic receptor agonists for the treatment of inflammatory diseases - Google Patents

Nicotinic receptor agonists for the treatment of inflammatory diseases

Info

Publication number
HK1098155A1
HK1098155A1 HK07105810.0A HK07105810A HK1098155A1 HK 1098155 A1 HK1098155 A1 HK 1098155A1 HK 07105810 A HK07105810 A HK 07105810A HK 1098155 A1 HK1098155 A1 HK 1098155A1
Authority
HK
Hong Kong
Prior art keywords
treatment
inflammatory diseases
receptor agonists
nicotinic receptor
nicotinic
Prior art date
Application number
HK07105810.0A
Other languages
English (en)
Inventor
Yvon Cormier
Evelyne Israel-Assayag
Marie-Renee Blanchet
Rene C Gaudreault
Philippe Labrie
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/890,987 external-priority patent/US20050130990A1/en
Application filed by Univ Laval filed Critical Univ Laval
Publication of HK1098155A1 publication Critical patent/HK1098155A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/037—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements with quaternary ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK07105810.0A 2004-07-15 2007-05-31 Nicotinic receptor agonists for the treatment of inflammatory diseases HK1098155A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/890,987 US20050130990A1 (en) 2001-03-23 2004-07-15 Nicotinic receptor agonists for the treatment of inflammatory diseases
PCT/CA2005/001120 WO2006005195A1 (en) 2004-07-15 2005-07-15 Nicotinic receptor agonists for the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
HK1098155A1 true HK1098155A1 (en) 2007-07-13

Family

ID=35783487

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07105810.0A HK1098155A1 (en) 2004-07-15 2007-05-31 Nicotinic receptor agonists for the treatment of inflammatory diseases

Country Status (17)

Country Link
EP (1) EP1773779B1 (ja)
JP (1) JP4783787B2 (ja)
KR (1) KR100860903B1 (ja)
CN (2) CN102872022A (ja)
AU (1) AU2005262174C1 (ja)
BR (1) BRPI0513305A (ja)
CA (1) CA2573977C (ja)
DK (1) DK1773779T3 (ja)
ES (1) ES2445751T3 (ja)
HK (1) HK1098155A1 (ja)
IL (1) IL180721A (ja)
MX (1) MX2007000576A (ja)
NO (1) NO20070789L (ja)
NZ (1) NZ553211A (ja)
PL (1) PL1773779T3 (ja)
RU (1) RU2414461C2 (ja)
WO (1) WO2006005195A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
WO2008103818A1 (en) * 2007-02-21 2008-08-28 University Of Louisville Research Foundation Therapeutic cotinine compositions
CA2937920C (en) 2013-03-13 2018-11-06 Universite Laval Preparation and method for use in the treatment of respiratory diseases
US9949984B2 (en) 2014-04-03 2018-04-24 UNIVERSITé LAVAL Method for use of homopiperazinium compounds in the treatment of cancer
US10639300B2 (en) 2016-04-12 2020-05-05 Arturo Solis Herrera Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
KR101976633B1 (ko) 2017-04-27 2019-05-09 서울대학교산학협력단 폐 섬유증의 예방 또는 치료용 약학적 조성물
US20200230213A1 (en) * 2017-10-03 2020-07-23 The Johns Hopkins University Lung cell treatments to prevent or treat disease
KR102115557B1 (ko) 2018-10-29 2020-05-26 서울대학교산학협력단 폐 섬유증의 예방 또는 치료용 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3402039A (en) * 1966-12-05 1968-09-17 Dow Chemical Co Piperazinium salts as plant stunting agents
SE0001075D0 (sv) * 1999-09-01 2000-03-27 Laszlo Bense Användning av åtminstone ett nikotinbaserat ämne och/eller ett ur detta ämne framställt ämne för tillverkning av ett medikament samt förfarande för behandling av obstruktiva lungsjukdomar
CA2441096C (en) * 2001-03-23 2009-06-30 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
FR2852830B1 (fr) * 2003-03-24 2008-04-18 Oreal Composition de teinture des fibres keratiniques comprenant un derive de para-phenylenediamine cationique substitue par un cycle diazacyclohexane ou diazacycloheptane

Also Published As

Publication number Publication date
AU2005262174B2 (en) 2009-10-08
IL180721A0 (en) 2007-06-03
WO2006005195A1 (en) 2006-01-19
CN101001843B (zh) 2014-08-27
NZ553211A (en) 2010-11-26
KR20070085207A (ko) 2007-08-27
BRPI0513305A (pt) 2008-05-06
RU2007105582A (ru) 2008-08-20
CA2573977C (en) 2012-04-10
AU2005262174A2 (en) 2006-01-19
JP2008505938A (ja) 2008-02-28
EP1773779B1 (en) 2013-12-04
JP4783787B2 (ja) 2011-09-28
EP1773779A1 (en) 2007-04-18
CN102872022A (zh) 2013-01-16
MX2007000576A (es) 2007-06-25
CA2573977A1 (en) 2006-01-19
IL180721A (en) 2012-10-31
KR100860903B1 (ko) 2008-09-29
EP1773779A4 (en) 2009-09-23
DK1773779T3 (da) 2014-02-10
AU2005262174C1 (en) 2010-05-06
CN101001843A (zh) 2007-07-18
PL1773779T3 (pl) 2014-04-30
NO20070789L (no) 2007-03-21
ES2445751T3 (es) 2014-03-05
AU2005262174A1 (en) 2006-01-19
RU2414461C2 (ru) 2011-03-20

Similar Documents

Publication Publication Date Title
ZA200707498B (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
ZA200608955B (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
HK1098155A1 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
ZA200700384B (en) Hydantoin derivatives for the treatment of inflammatory disorders
IL187302A0 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
HK1186125A1 (en) Quinoline derivatives for the treatment of latent tuberculosis
HK1138850A1 (en) Quinoline derivatives for the treatment of inflammatory diseases
ZA200806072B (en) Hydantoin derivatives for the treatment of inflammatory disorders
IL191772A0 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
IL191637A0 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
IL192692A0 (en) Compounds for the treatment of inflammatory disorders
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
AP2006003828A0 (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
ZA200806293B (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
ZA200703125B (en) Substituted pteridines for treating inflammatory diseases
EP1806145A4 (en) MEDICINE FOR THE TREATMENT OF INFLAMMATORY DISEASES
ZA200705160B (en) Quinoline derivatives for the treatment of latent tuberculosis
GB0526394D0 (en) Treatment of inflammatory diseases
ZA200709777B (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
IL194261A0 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
GB0425054D0 (en) Formamide derivatives for the treatment of diseases
GB0405995D0 (en) Combination for treating inflammatory diseases
GB0405994D0 (en) Combination for treating inflammatory diseases
IL202502A0 (en) Agents for the treatment of inflammatory diseases and methods of using same

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220715